Moderna, Inc (MRNA)

Etorro trading 970x250
Moderna, Inc (MRNA) Logo

About Moderna, Inc

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., and Recipharm for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Address: 200 Technology Square, Cambridge, MA, United States, 02139

Moderna, Inc News and around…

Latest news about Moderna, Inc (MRNA) common stock and company :

Recent Weakness May Mean Opportunity With Moderna Stock
19 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you already own MRNA stock, it's too early to sell. If you do not yet own it? It's not too late to buy. The post Recent Weakness May Mean Opportunity With Moderna Stock appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

How innovations in Covid-19 testing will play a part in this winter season
19 Oct, 2021 Yahoo! Finance

Thierry Bernard, QIAGEN CEO, joins Yahoo Finance to discuss the future of Covid-19 testing, interest and supply of at-home covid testing, and the diagnostic industry amid the pandemic.

Which Vaccine Stock Will Benefit Most From FDA's "Mix And Match" Approval?
19 Oct, 2021 FinancialContent

On Tuesday, it became clear that the FDA plans to allow for a “mix and match” approach to vaccine booster shots, ...

Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
19 Oct, 2021 Yahoo! Finance

Is (MRNA) Outperforming Other Medical Stocks This Year?

Is Now a Good Time to Buy Ocugen?
19 Oct, 2021 FinancialContent

There is a lot of uncertainty surrounding this biotech's prospects.

Johnson & Johnson CFO talks earnings, vaccines
19 Oct, 2021 Yahoo! Finance

Johnson & Johnson CFO Joseph J. Wolk joins Yahoo Finance Live to discuss Johnson & Johnson’s recent earnings, the effectiveness of its vaccine, and the importance of innovation.

U.S. COVID-19 death toll tops 726,000 amid report FDA to allow people mix and match vaccine booster shots
19 Oct, 2021 FinancialContent

The U.S. death toll from the coronavirus-borne illness COVID-19 rose above 726,000 on Tuesday, as a report said the Food and Drug Administration is moving to allow people get booster shots of vaccines that are different from their primary doses.

FDA May Allow 'Mix and Match' Regime For COVID-19 Booster Shots: NYT
19 Oct, 2021 FinancialContent

The FDA is planning to allow Americans to get a different booster shot of a COVID-19 vaccine than the one initially taken, ...

Johnson & Johnson May Not Have to Wait Long for Its Next Blockbuster Vaccine
19 Oct, 2021 FinancialContent

This vaccine could come from its candidate that prevents a little-known respiratory virus.

The FDA May Approve ‘Mix-and-Match’ Booster Shots as Soon as This Week
19 Oct, 2021 Yahoo! Finance

The FDA is moving to soon allow people to have a Covid-19 booster shot different from the vaccine they initially received, according to reports.

Vaccine-Makers Up on Likely FDA OK for Mix and Match Covid Booster
19 Oct, 2021 Yahoo! Finance

By Dhirendra Tripathi

Why Johnson & Johnson Will Be a Bigger Winner With Boosters Than Pfizer and Moderna
19 Oct, 2021 FinancialContent

At least initially. It could be a different story over the longer term.

Stocks Gain, SEC GameStop Report, Rent The Runway IPO - 5 Things You Must Know
19 Oct, 2021 Yahoo! Finance

Stocks edge higher ahead of earnings; SEC says GameStop surge powered by believers; FDA set to approve "mix & match' COVID boosters; DraftKings faces Entain bid deadline and Rent the Runway seeks $1.3 billion valuation in Nasdaq IPO.

FDA may soon approve mixing and matching COVID booster shots
18 Oct, 2021 FinancialContent

The Food and Drug Administration is moving to soon allow people to receive booster shots that are different from their first COVID-19 vaccine doses, people familiar with the matter said.

Decision On Moderna's COVID-19 Vaccine For Adolescents Delayed - What You Need To Know
18 Oct, 2021 FinancialContent

The FDA is delaying its decision to authorizeModerna Inc's(NASDAQ: MRNA) COVID-19 vaccine for adolescents to assess ...

Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
18 Oct, 2021 FinancialContent

Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral antivirals

Will Covid-19 Booster Approval Boost Moderna Stock? Analyst Weighs In
18 Oct, 2021 Yahoo! Finance

The regulators might be uncertain whether Moderna’s (MRNA) Covid-19 vaccine is suitable for younger people, but an FDA panel was unanimous in agreement when considering the use of its booster shot. The committee voted 19-0 in favor of a Spikevax booster to be administered at least 6 months following completion of the primary vaccines for individuals over 65, for those between ages 18 to 64 who are at risk either for medical reasons or via occupation and for people in long-term care. So, good new

Moderna's Covid Booster Shot Is Next On Deck — But Is Moderna Stock A Buy?
18 Oct, 2021 Yahoo! Finance

Is Moderna stock a buy as the FDA and CDC prepare to look at booster shot data from Moderna and Johnson & Johnson?

Allison Williams leaves ESPN over vaccine mandate: ‘I cannot put a paycheck over principle’
18 Oct, 2021 FinancialContent

The longtime sideline reporter said ESPN denied her request for accommodation to not receive the vaccine.

Why Moderna Shares Are Rebounding From Friday's Losses
18 Oct, 2021 FinancialContent

Moderna, Inc. (NASDAQ: MRNA) shares have followed a downtrend ever since completing a double top formation in late September. After ...

U.S. may soon authorize boosters for all 3 in-use vaccines, as experts renew plea for unvaccinated to get their shots
18 Oct, 2021 FinancialContent

A Food and Drug Administration advisory committee voted unanimously Friday that allowing adults who were initially vaccinated with the Johnson & Johnson one-dose vaccine against COVID-19 to get a booster is safe and effective, freeing the way for the agency to authorize its use.

Why Moderna Stock Is Up By 4% Today
18 Oct, 2021 Yahoo! Finance

The stock is trying to settle above $335.

Why Moderna Stock Is Rising Today
18 Oct, 2021 FinancialContent

There's a super-bullish estimate for Moderna's 2022 sales.

Fauci Expects Regulators to Approve Mixing Vaccine Doses
18 Oct, 2021 Yahoo! Finance

The idea is to offer additional flexibility so that Americans in certain situations can receive booster doses of a different vaccine than they received for their initial dose.

J&J, Moderna COVID-19 Booster Jabs Near FDA Authorization
18 Oct, 2021 Yahoo! Finance

The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.

Is Moderna a Good Healthcare Stock to Buy Now?
18 Oct, 2021 FinancialContent

The vaccine maker has a promising pipeline but an expensive valuation.

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
18 Oct, 2021 FinancialContent

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market ...

Can Pfizer and GlaxoSmithKline Beat Johnson & Johnson's RSV Vaccine?
17 Oct, 2021 FinancialContent

J&J has set a high bar for its rivals.

2 Biotech Stocks Poised for Jaw-Dropping Growth
17 Oct, 2021 FinancialContent

These two tiny drugmakers could make early shareholders wealthy.

Will New COVID-19 Vaccines Be Needed in 2022?
17 Oct, 2021 FinancialContent

One biotech CEO thinks so.

Moderna, Inc (MRNA) is a NASDAQ Common Stock listed in , ,

970x250